Congress expands Medicaid mental health coverage, removing 50-year-old barrier

What it does

This bill removes a decades-old federal restriction that bars Medicaid from paying for mental health and substance-use treatment in standalone psychiatric hospitals and facilities (called 'institutions for mental diseases' or IMDs) for patients under 65. Currently, Medicaid covers such care only for seniors; this bill extends that coverage to younger adults, provided the facilities meet federally approved standards for mental health and addiction treatment. The change takes effect 180 days after enactment.

Why we flagged it

The bill's core function is to expand Medicaid eligibility for psychiatric inpatient care by removing an age-based exclusion. It is a public-health measure that increases access to a covered benefit, not a deregulation, subsidy, or carve-out.

What the text implies

• Removal of the IMD exclusion may increase Medicaid spending significantly, depending on state uptake and utilization rates; the bill does not cap enrollment or impose per-patient limits, leaving cost exposure open.
• The bill delegates standard-setting to the Secretary of Health and Human Services, creating regulatory discretion over what facilities qualify; standards are not defined in statute, potentially allowing future administrations to narrow or broaden eligibility through rulemaking.
• States retain discretion to implement or not; the bill does not mandate state participation, so coverage expansion may be uneven across states, creating geographic disparities in access.
• The 180-day implementation window is tight for states to update systems, train staff, and establish payment rates; rushed implementation could create access bottlenecks or payment delays.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens with mental illness or substance-use disorders gain access to Medicaid-covered psychiatric hospitalization and treatment that was previously unavailable to them under age 65. This removes a structural barrier to care and expands a public health benefit. The bill conditions coverage on evidence-based standards, protecting quality.

Who stands to gain

• psychiatric hospitals and inpatient mental health facilities (private and nonprofit)
• substance-use disorder treatment centers
• pharmaceutical companies (increased treatment volume may increase medication use)
• mental health service providers and clinicians

Named in the bill

Social Security Act Title XIX (Medicaid), Institution for Mental Diseases (IMD), Secretary of Health and Human Services, American Society of Addiction Medicine, State Medicaid agencies, Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

• Dec 15, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 15, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $30,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Ritchie Torres, the sponsor, reported $758,550 in PAC receipts in the 2026 cycle.

• Sheppard Pratt Health System — $30,000 on 1 filing

Lobbying Disclosure Act filings through Jul 24, 2026. A filing shows who paid to lobby on a bill it names, not what changed.